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Abstract
Atrial fibrillation (AF) is a common arrhythmia of
substantial public health importance. Recent evidence
demonstrates a heritable component underlying AF,
and genetic discoveries have identified common
variants associated with the arrhythmia. Ultimately
one hopes that the consideration of genetic variation
in clinical practice may enhance care and improve
health outcomes. In this review we explore areas of
potential clinical utility in AF management including
those relating to pharmacogenetics and risk
prediction.
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Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia
marked by loss of coordinated atrial electrical and
mechanical function. Among the potential consequences
of AF are symptoms and decreased functional status [1],
as well as increased risks of thromboembolic stroke,
heart failure, and mortality [2]. Thus far, efforts to pre-
vent AF have generally been limited, and therefore man-
agement is directed at preventing or alleviating adverse
consequences of the arrhythmia.
In recent years, heritability underlying AF has been
recognized [3-7]. AF risk is increased by about 40% if a
first-degree relative has AF, and two-fold if that relative
develops AF by age 65 [7]. Numerous genetic variants
associated with AF have been reported through traditional
mapping techniques such as linkage and candidate gene
analyses [8]. For example, novel gain-of-function muta-
tions in KCNE1 were recently described in this journal
using a candidate gene approach in patients with early
onset AF [9]. KCNE1 encodes the beta subunit of the
potassium channel comprising the IKs current, which gov-
erns atrial repolarization. Such gain-of-function mutations,
and their expected shortening of the action potential dura-
tion, are consistent with electrical reentry as a predomi-
nant pathophysiological mechanism underlying AF [10].
Mutations in sodium, potassium, and calcium channel
subunits, as well as in gap junction and non-ion channel
proteins have been reported and are reviewed elsewhere
(Table 1) [8,11].
Large-scale genome-wide association studies have iden-
tified nine common AF susceptibility loci (Table 1)
[12-16]. In aggregate, these discoveries implicate cardiac
ion channels, transcription factors central to cardiopul-
monary development, and signaling molecules as common
pathways involved in the development of AF. Prior to
these genetic discoveries, the relations between many of
these pathways and AF pathogenesis were unrecognized.
Genetic associations with AF have spawned an exciting
new era of biological investigation. Integrating recent dis-
coveries with previous insights about atrial remodeling
and AF pathophysiology has led to resurgence of interest
in exploiting biological pathways with pharmaceuticals for
AF management [17,18]. Given the strong heritable com-
ponent underlying AF, these discoveries also have elicited
hope that determining genetic variation in patients will
help individualize clinical management and improve
health outcomes. The concept of applying knowledge of
an individual’s genotype to clinical management is com-
monly referred to as personalized or precision medicine.
In many ways, as with most areas of clinical medicine,
the management of patients with AF is already persona-
lized [19,20]. Prescription of thromboembolism prophy-
laxis regimens is tailored for each patient. Bedside stroke
and bleeding risk prediction rules [21-24] are available to
help clinicians decide whether to prescribe aspirin or sys-
temic anticoagulants. Cardioversions, antiarrhythmic
therapy, and ablation for AF are variably prescribed
depending on patient symptoms. When choosing which
systemic anticoagulants or antiarrhythmic medications to
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prescribe, clinicians consider comorbidities, drug efficacy,
adverse effects, contraindications, pharmacologic interac-
tions, and cost. Ablation procedures for patients with
persistent AF are more extensive than for those with par-
oxysmal AF [25].
Despite the personalized nature of AF management,
care of patients with AF is challenging owing to the
complexity of the arrhythmia. Patient management is
limited by unpredictable recurrence and progression of
AF, differing susceptibilities to stroke and heart failure,
and variable treatment responses. These challenges are
opportunities for diagnostic and therapeutic innovation,
and represent areas where genetic medicine might facili-
tate clinical management. Two promising areas for the
near-term application of genetic information in AF
include pharmacological management and risk predic-
tion (Table 2).
Potential areas for clinical application of genetic
information
Pharmacogenetics
Many medications used for AF treatment have narrow
therapeutic margins. Antiarrhythmic efficacy is only
about 50% at 12 months [26], and prohibitive adverse
effects such as proarrhythmia or other reactions may
occur [27,28]. Thromboembolism prophylaxis with war-
farin is limited by increased risks of disabling stroke
among subtherapeutic patients, and bleeding among
those with supratherapeutic doses [29].
Can the effectiveness and safety of pharmacologic agents
used in AF be improved by utilizing genetic information?
Pharmacogenetics refers to how genetic variation
accounts for differences in drug responses among indivi-
duals. Measurable differences in pharmacodynamics
(that is, the interaction of drugs with their target mole-
cules) and pharmacokinetics (that is, properties relating
to drug uptake, distribution, duration of effect, metabo-
lism, excretion, and so on) are likely to be associated
with genetic variation. In a recent proof-of-concept
paper, whole genome sequencing in a single individual
identified over 60 previously reported pharmacogenetic
variants affecting drug response [30].
A high-profile example of a pharmacogenetic effect
relevant to AF management relates to warfarin. War-
farin dose requirements have been linked to variation in
Table 1 Atrial fibrillation (AF) susceptibility genes and loci
AF susceptibility genes AF susceptibility loci
Gene Mechanism Ref. Chromosomal locus Candidate gene Ref.
Potassium channel Large-scale candidate gene or genome-wide
association study
KCNQ1 Enhanced repolarization (increased IKs) [61-65] 1q21 IL6R [66]
KCNE1 Enhanced repolarization (increased IKs) [9,67-69] 1q21 KCNN3 [15,16]
KCNE2 Enhanced repolarization (increased IKs) [70] 1q24 PRRX1 [16]
KCNE5 Enhanced repolarization (increased IKs) [71] 4q25 PITX2 [12-16]
KCNH2 Enhanced repolarization (increased IKr) [72,73] 7q31 CAV1 [16]
KCNJ2 Enhanced repolarization (increased IK1) [74] 9q22 C9orf3 [16]
KCNA5 Delayed repolarization and afterdepolarizations (decreased IKur) [75] 10q22 SYNPO2L/MYOZ1 [16]
Sodium channel 14q23 SYNE2 [16]
SCN5A Hyperpolarizing shift in inactivation (loss-of-function)/depolarizing shift
in inactivation (gain-of-function)
[76-81] 15q24 HCN4 [16]
SCN1B Decreased INa current and altered channel gating [82] 16q22 ZFHX3 [16]
SCN2B Decreased INa current and altered channel gating [82] Familial loci without known gene
Ion channel-related 6q14-q16 - [83]
GJA5 Impaired cellular transport and intercellular electrical coupling,
increased dispersion of refractoriness
[84-87] 10p11-q21 - [88]
ANK2 Loss-of-function reduces expression and membrane targeting of Cav1.3
(decreased ICa,L)
[89,90] 10q22-q24 - [91]
Non-ion channel
LMNA Disruption of nuclear function or altered interaction with cytoplasmic
proteins
[92-95]
NUP155 Reduced nuclear membrane permeability, enhanced repolarization [96,97]
AGT Unknown [98,99]
ACE Insertion/deletion, unknown mechanism [100-102]
NPPA Mutant peptide, enhanced repolarization [103]
AF susceptibility genes were based on prior linkage mapping or candidate gene sequencing efforts. AF susceptibility loci were based on candidate gene chip or
genome-wide association studies.
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CYP2C9 [31] and VKORC1 [32], genes encoding pro-
ducts involved in warfarin pharmacokinetics and phar-
macodynamics, respectively. Dosing algorithms that
include genetic variation in these genes explain a strik-
ing one-third to one-half of the variability in warfarin
dose requirements [33]. Accounting for variants in these
genes may be particularly beneficial (1) during initiation
of warfarin therapy when complications relating to
excessive or underdosing are particularly prevalent, and
(2) for identifying individuals with unexpectedly high or
low therapeutic dose requirements [34] who may there-
fore be at elevated risk for thromboembolism or bleed-
ing, respectively. The US Food and Drug Administration
has advised physicians that genetic testing may improve
initial dosing estimates among patients taking warfarin
[35] and dosing prediction algorithms are available.
Nevertheless, routine warfarin testing has not been
widely adopted for several reasons. Novel anticoagulants
[36] and procedures [37] are emerging as potential alter-
natives to warfarin, rigorous surveillance may improve
time spent in the therapeutic range thereby improving
safety and efficacy [38], and logistical considerations
such as costs and genetic literacy pose challenges to the
adoption of genetic testing. Currently, the safety and
efficacy of genotype-guided warfarin dosing is being
compared to routine dosing in the ongoing Clarification
of Optimal Warfarin Dosing through Genetics (COAG)
trial (clinicaltrials.gov identifier NCT00839657).
Regardless of the outcome of this trial, the striking
associations between genetic variants and warfarin doses
have revealed the clinical potential for pharmacoge-
netics. Emerging reports demonstrate other associations
between genetic variants and drug response. Genetic
variation has been reported to associate with response
to b-adrenergic antagonism in patients with AF [39],
and genetic variation associates with drug-induced tor-
sade de pointes [40,41]. Given the heterogeneity in the
molecular mechanisms underlying AF [42], as well as
variability in medication efficacy and adverse effects,
there may be a practical role for pharmacogenetics in
the management of patients with this arrhythmia. It is
worth noting that genetic variation has also been
reported to associate with AF recurrence after catheter
ablation [43]; however, the role of genetic testing for a
procedure in which success is dependent on many tech-
nical factors remains undefined.
The next steps for assessing the clinical utility of phar-
macogenetics will involve performing systematic pheno-
typing, genotyping, and association testing of established
and novel pharmacological agents used for AF manage-
ment. Candidate genes that ought to be prioritized for
screening include those encoding products involved in
drug uptake or metabolism, and those encoding drug
targets.
Risk prediction
Risk prediction encompasses estimation of AF probabil-
ity and prediction of AF-related complications such as
stroke, heart failure, and death. The goal of prediction
algorithms is to identify individuals prior to the onset of
AF or AF-related morbidity, and thereby help target
prevention efforts. Estimation of risk may also assist
with clinical trial development by enabling enrollment
of individuals in a particular risk stratum.
Table 2 Potential areas for clinical application of genetic discoveries in atrial fibrillation (AF) management
Area Example Potential utility Limitations
Risk
prediction
Predict new-onset AF or AF-related morbidity (stroke,
heart failure, mortality risk)
Benchmark for clinical trial
development
Absence of known preventive strategies for AF
Facilitate AF and clinical
outcome prevention
Cohorts for genetic risk score derivation
predominantly of European ancestry
Small relative risks of discovered variants




Predict AF progression Early antiarrhythmic or
ablation intervention





Pharmacogenetics Maximize efficacy, minimize
adverse effects




Ablation and mechanical interventions as
alternatives
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Clinical prediction algorithms for new-onset AF have
been developed in community-based cohorts of Eur-
opean and African American ancestry [44-46]. These
algorithms have good but not excellent discriminative
properties. In a given sample of individuals without AF,
they correctly assigned a higher predicted risk to those
who ultimately developed AF only about 60% to 70% of
the time [44-46]. Simply flipping a coin would correctly
assign a higher risk to those developing AF 50% of the
time.
Can genetic discoveries improve risk prediction?
We and other investigators from the Framingham Heart
Study tested whether accounting for the occurrence of
AF in a first-degree relative (familial AF) improved AF
risk prediction beyond clinical risk factors [7]. AF pre-
diction improved slightly after accounting for familial
AF. In a separate study from Sweden, adding genotypes
for two common polymorphisms at the chromosome
4q25 and 16q22 AF susceptibility loci to clinical risk
factors did not significantly improve AF risk prediction
[47].
For most complex conditions, genetic risk scores have
not achieved substantial improvements in discrimination
over scores comprised of clinical risk factors. Yet
enhancements in the understanding of genetic risk mod-
eling reveal insights that may improve the utility of
genetic risk scores in the future. For example, variants
included in genetic risk scores to date have small effect
sizes (for example, relative risks of 1.1 to 1.5). Single
risk factors with such modest relative risks are unlikely
to have meaningful impacts on discrimination alone
[48]. Large-effect variants, which have greater potential
to improve discrimination, are rare and not captured by
genotyping panels used in genome-wide association
studies.
Fine mapping and sequencing offer promise for the
discovery of such large-effect variants [49]. For example
in a fine mapping analysis we previously identified inde-
pendent genetic variants at the chromosome 4q25 locus
associated with AF [50]. A multimarker risk score com-
prised of genotypes tagging these three independent sig-
nals demonstrated that AF risk increased with an
increasing number of AF risk alleles. The multimarker
score identified about 12% of individuals with a twofold
or greater relative risk for AF, and 1% with an estimated
sixfold elevated risk of AF compared to those with the
most common genotypes. This is one of the largest rela-
tive risks to date for a qualitative trait in the era of gen-
ome-wide association studies.
Another potential reason that genetic risk scores have
not substantially improved prediction models is that few
variants were tested. Accounting for additional genetic
variants associated with conditions at far less stringent
significance thresholds can substantially increase the
proportion of variance explained by genetic factors
[51-53]. In simulations, genetic profiling using large
numbers of genetic variants significantly improved risk
discrimination [54].
Novel metrics have been developed to assess clinical
utility of prediction models, with increased recognition
that measures of discrimination alone can be insensitive
[55]. The role of novel prediction metrics with respect
to genetic profiling has not been extensively explored.
Furthermore, although a widespread heritable compo-
nent underlies AF, the arrhythmia may result from a
variety of different pathological processes. Whether
genetic profiling will successfully predict incident AF
may depend on the extent to which the ‘type’ of AF stu-
died is influenced by genetic factors. The importance of
refining AF classification has been highlighted elsewhere
[56,57], and may overcome the potential challenges that
phenotypic heterogeneity presents to risk prediction
efforts.
The absence of data demonstrating clinical utility of
routinely using genotype information to guide clinical
management in AF should not deter hope at this stage,
but rather should be viewed as an opportunity for sys-
tematic testing of the clinical role of genetic informa-
tion. Nevertheless, there is a risk that hype can obscure
the monumental insights gained from the current era of
genetic discovery. As an example, companies such as
deCODE and 23andMe are performing direct to consu-
mer genetic testing, and purport to calculate one’s
genetic risk of AF based on one or a few polymorphisms
associated with modestly increased relative risks of AF.
These calculations are not based on well-defined genetic
effect estimates, and do not consider other genetic risk
factors, interactions between genes, the predictive utility
of genetic risk markers, or competing risks. Moreover,
in the absence of data regarding clinical risk factors and
environmental exposures, how are these results to be
interpreted? Problems with direct to consumer genetic
testing are reinforced by recent literature highlighting
the facts that patients often have misperceptions about
the results genetic testing [58], and practitioners fre-
quently lack confidence in explaining direct to consumer
genetic testing results [59].
Summary
Owing to the absence of currently available outcome
data, there is insufficient evidence to recommend rou-
tine testing for genetic variation in the management of
patients with AF, as was highlighted by a recent Heart
Rhythm Society and European Heart Rhythm Associa-
tion consensus statement on genetic testing [60]. How-
ever, increased attention to pharmacogenetics and
prediction modeling using genetic information offers
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hope for improved clinical care. The absence of data
demonstrating direct utility of incorporating genotype
information into clinical practice provides an opportu-
nity to systematically assess whether applying genetic
data to clinical practice will enhance outcomes.
As with any new technology or development, systematic
assessment of its utility in clinical medicine is warranted.
Such assessment includes identifying suboptimal realms of
clinical care, determining whether such areas present
opportunities for application of genetic knowledge, testing
whether genetic discoveries are superior to standard care
for improving health outcomes, and evaluating whether
the expected benefits of implementing genetic testing jus-
tify the resource utilization that would be necessary for its
adoption.
Recent AF genetic discoveries herald a sea change in
the approach to AF research. Investigation of the patho-
genic mechanisms underlying this common and morbid
arrhythmia is now informed by unbiased techniques,
allowing investigators to branch out from preconceived
biological mechanisms and reliance on established animal
models of AF. It will take many years to realize the full
impact of recent genetic discoveries. In the meantime,
questions surrounding the utility of applying genetic dis-
coveries to patient management will only be clarified by
rigorous testing of genetic information in clinical prac-
tice. Ultimately, it is the opportunity for innovation, dis-
covery, and improvement in health outcomes that makes
this era of genetic discovery so exciting.
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